Fabtech Technologies Limited , a global turnkey engineering solutions provider for the pharmaceutical, healthcare, and biotech sectors, has reported strong financial results for the first half of fiscal year 2026. The company's performance highlights its growing presence in pharmaceutical emerging markets and its focus on enabling medicinal independence across various regions.

Financial Highlights

• Total income reached INR 19,322.80 lakhs, marking a substantial year-on-year growth of 109.9%
• Net profit stood at INR 2,198.02 lakhs, up 101.6% compared to the same period last year
• EBITDA improved to INR 2,839.99 lakhs, with margins expanding to 14.7%

Strong Order Book and Market Presence

Fabtech Technologies maintains a robust order book of INR 90,441.87 lakhs as of July 31, 2025, providing clear visibility for sustained revenue momentum in the coming quarters. The company has reported a 7-9% growth in its order book from July to September 2025, indicating continued market traction.

Global Expansion and Project Execution

• Operating across 22 countries, with a focus on MENA, GCC, and ECO Zone regions
• Secured several high-value turnkey projects in markets investing in pharmaceutical self-reliance and healthcare infrastructure
• Average project execution timeline of 18-24 months, from concept and design to complete supply chain and execution

Business Model and Capabilities

Fabtech Technologies offers end-to-end turnkey solutions for pharmaceutical and biotech manufacturing setups, focusing on three critical pillars:

1. Process systems
2. Air management
3. Water purification and distribution

The company's asset-light model, supported by in-house manufacturing capabilities, enhances execution agility and scalability while maintaining cost efficiency. Approximately 30% of the products supplied in turnkey projects are manufactured in-house.

Market Outlook and Strategy

Ashwani Kumar Singh, Chief Executive Officer of Fabtech Technologies, commented on the company's performance and outlook: "The first half of FY '26 has been a period of strong growth and strategic progress for the company. We continue to build on our execution excellence, expand our presence across key international markets, and strengthen our leadership as a global turnkey engineering solution provider to the life science and healthcare sector."

The company remains focused on strengthening its global footprint, deepening its presence in high-growth regions, and driving sustainable profitability. Fabtech Technologies is committed to building long-term relationships with clients by consistently delivering quality, reliability, and compliance across all projects.

As pharmaceutical emerging markets move towards medicinal independence, Fabtech Technologies is well-positioned to capitalize on the growing demand for end-to-end turnkey solutions in the life sciences sector.

Looking Ahead

While the company does not provide specific quarterly guidance due to the project-based nature of its business, management expressed confidence in sustaining growth and improving upon previous year's performance. Fabtech Technologies aims to maintain its focus on operational efficiency, strategic partnerships, and technology-led innovation to drive long-term value creation for its stakeholders.

Fabtech Technologies Limited , a leading turnkey engineering solutions provider for the pharmaceutical and healthcare sectors, has announced impressive financial results for the second quarter of fiscal year 2026, showcasing substantial growth across key metrics. The company is also targeting rapid growth in several key areas of the bio-pharma sector.

Financial Highlights

The company's performance for the first half of FY26 also demonstrated strong growth:

Operational Performance

Fabtech Technologies continues to strengthen its position in the global market:

• Operations across 62 countries
• Current order book of ₹90,441.87 lakhs as of July 31, 2025
• 78% of revenue derived from MENA, GCC, and ECO Zone markets
• 135 projects delivered globally

Business Overview and Growth Strategy

Fabtech Technologies Limited specializes in providing start-to-finish turnkey solutions for pharmaceutical, biotech, and healthcare facilities worldwide. The company's integrated approach covers design, engineering, manufacturing, and validation to build GMP-compliant, energy-efficient, and contamination-controlled environments.

The company is targeting rapid growth across three key areas:

1. Bio-pharma equipment
2. Modular facilities
3. Engineering turnkey projects

Fabtech reports strong order visibility from vaccine manufacturing and API expansion projects. To strengthen margins and scale exports from India as a key pharma engineering hub, the company is focusing on:

• Technology integration
• Global partnerships
• Backward integration

Market Position

The company's growth has been accelerated by the MEA region's focus on pharmaceutical self-reliance post-COVID. Fabtech's asset-light, integrated model combines in-house manufacturing, advanced project execution, and minimal third-party dependency, ensuring speed, quality, and consistency in project delivery.

Future Outlook

With 20 secured projects worth ₹13,724.61 lakhs, Fabtech Technologies Limited is well-positioned to continue its growth trajectory. The company's expertise in Bio-Clean Air, Pure Water, and Precision Process Systems positions it as a key player in building resilient, sustainable, and future-ready healthcare manufacturing ecosystems globally.

Fabtech Technologies Limited's strong Q2 FY26 results reflect its robust business model and strategic positioning in the pharmaceutical and healthcare engineering solutions market. The significant year-over-year growth in revenue and profitability underscores the company's ability to capitalize on the increasing demand for turnkey engineering solutions in the life sciences sector.